ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Testosterone therapy in hypogonadal patients and the associated risks of cardiovascular events
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 180851" data-attributes="member: 13851"><p><strong>ABSTRACT</strong></p><p></p><p>Since the male secondary sex characters, libido and fertility are attributed to their major androgen hormone testosterone, the sub-optimum levels of testosterone in young adults may cause infertility and irregularities in their sexual behaviour. Such deficiency is often secondary to maladies involving testes, pituitary or hypothalamus that could be treated with an administration of exogenous testosterone. In the last few decades, the number of testosterone prescriptions has markedly increased to treat sub-optimal serum levels even though its administration in such conditions is not yet approved. On account of its associated cardiovascular hazards, the food and drug authority in the United States has issued safety alerts on testosterone replacement therapy (TRT). Owing to a great degree of conflict among their findings, the published clinical trials seem struggling in presenting a decisive opinion on the matter. Hence, the clinicians remain uncertain about the possible cardiovascular adversities while prescribing TRT in hypogonadal men. The uncertainty escalates even further while prescribing such therapy in older men with a previous history of cardiovascular ailments. <em><span style="color: rgb(184, 49, 47)">In the current review, we analysed the pre-clinical and clinical studies to evaluate the physiological impact of testosterone on cardiovascular and related parameters. We have enlisted studies on the association of cardiovascular health and endogenous testosterone levels with a comprehensive analysis of epidemiological studies, clinical trials, and meta-analyses on the cardiovascular risk of TRT. The review is aimed to assist clinicians in making smart decisions regarding TRT in their patients. </span></em></p><p><em></em></p><p><em></em></p><p><em></em></p><p><em></em></p><p><em></em></p><p><em></em></p><p><em></em></p><p><em></em></p><p><em><strong><span style="color: rgb(184, 49, 47)">7. </span><span style="color: rgb(0, 0, 0)">Conclusions </span></strong></em></p><p><em><strong></strong></em></p><p><em><strong><span style="color: rgb(184, 49, 47)">Besides its primary role in male secondary sex character, fertility, and sexual behaviour, testosterone plays a significant regulatory role in metabolism, growth and cardiovascular functions. </span></strong><span style="color: rgb(0, 0, 0)">Testosterone deficiency may result in Hypogonadism and other serious health disorders in the elderly as well as young men. Over the past few decades, the number of testosterone prescriptions has been alarmingly increased around the globe to treat hypogonadism. Thus far, the available reports including epidemiological studies, clinical trials and meta-analyses have generated conflicting opinions in establishing an association between cardiovascular adversities and TRT. </span><strong><span style="color: rgb(184, 49, 47)">According to some retrospective assessments, TRT exerts advantageous effects on mortality. Other studies including some randomized trials, have associated the likeliness of severe cardiovascular risks with TRT. Succinctly, the imperative shortcomings in the study design, selection criteria and result analyses of most of such clinical trials and epidemiological studies may account for such conflicting findings. Besides, none of the published documents on TRT trials have been sufficiently powered to evaluate cardiovascular issues.</span><span style="color: rgb(44, 130, 201)"> Consequently, the TRAVERSE trial was initiated in 2018 to evaluate the cardiovascular risks/safety of TRT. The study is designed for five years to get a better understanding of this context. </span><span style="color: rgb(184, 49, 47)">Meanwhile, to make smart decisions, clinicians should openly discuss with their patients about the prevailing data on the cardiovascular risks of TRT. </span></strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 180851, member: 13851"] [B]ABSTRACT[/B] Since the male secondary sex characters, libido and fertility are attributed to their major androgen hormone testosterone, the sub-optimum levels of testosterone in young adults may cause infertility and irregularities in their sexual behaviour. Such deficiency is often secondary to maladies involving testes, pituitary or hypothalamus that could be treated with an administration of exogenous testosterone. In the last few decades, the number of testosterone prescriptions has markedly increased to treat sub-optimal serum levels even though its administration in such conditions is not yet approved. On account of its associated cardiovascular hazards, the food and drug authority in the United States has issued safety alerts on testosterone replacement therapy (TRT). Owing to a great degree of conflict among their findings, the published clinical trials seem struggling in presenting a decisive opinion on the matter. Hence, the clinicians remain uncertain about the possible cardiovascular adversities while prescribing TRT in hypogonadal men. The uncertainty escalates even further while prescribing such therapy in older men with a previous history of cardiovascular ailments. [I][COLOR=rgb(184, 49, 47)]In the current review, we analysed the pre-clinical and clinical studies to evaluate the physiological impact of testosterone on cardiovascular and related parameters. We have enlisted studies on the association of cardiovascular health and endogenous testosterone levels with a comprehensive analysis of epidemiological studies, clinical trials, and meta-analyses on the cardiovascular risk of TRT. The review is aimed to assist clinicians in making smart decisions regarding TRT in their patients. [/COLOR] [B][COLOR=rgb(184, 49, 47)]7. [/COLOR][COLOR=rgb(0, 0, 0)]Conclusions [/COLOR] [COLOR=rgb(184, 49, 47)]Besides its primary role in male secondary sex character, fertility, and sexual behaviour, testosterone plays a significant regulatory role in metabolism, growth and cardiovascular functions. [/COLOR][/B][COLOR=rgb(0, 0, 0)]Testosterone deficiency may result in Hypogonadism and other serious health disorders in the elderly as well as young men. Over the past few decades, the number of testosterone prescriptions has been alarmingly increased around the globe to treat hypogonadism. Thus far, the available reports including epidemiological studies, clinical trials and meta-analyses have generated conflicting opinions in establishing an association between cardiovascular adversities and TRT. [/COLOR][B][COLOR=rgb(184, 49, 47)]According to some retrospective assessments, TRT exerts advantageous effects on mortality. Other studies including some randomized trials, have associated the likeliness of severe cardiovascular risks with TRT. Succinctly, the imperative shortcomings in the study design, selection criteria and result analyses of most of such clinical trials and epidemiological studies may account for such conflicting findings. Besides, none of the published documents on TRT trials have been sufficiently powered to evaluate cardiovascular issues.[/COLOR][COLOR=rgb(44, 130, 201)] Consequently, the TRAVERSE trial was initiated in 2018 to evaluate the cardiovascular risks/safety of TRT. The study is designed for five years to get a better understanding of this context. [/COLOR][COLOR=rgb(184, 49, 47)]Meanwhile, to make smart decisions, clinicians should openly discuss with their patients about the prevailing data on the cardiovascular risks of TRT. [/COLOR][/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Testosterone therapy in hypogonadal patients and the associated risks of cardiovascular events
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top